OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptiNose prioritizes XHANCE launch for sinusitis, eyes growth opportunities

OptiNose is focusing on profitability and preparing for the launch of XHANCE for chronic sinusitis, anticipating improved financial performance in 2023.
The company's strategic initiatives include exploring commercial partnerships, optimizing expenses, and evaluating potential sale options, indicating a proactive approach to growth.
While facing challenges in revenue generation and prescription volumes, OptiNose is leveraging strengths in financial stability, market reach, and growth opportunities.

OptiNose reports steady Q1 performance amidst revenue challenges and growth opportunities

OptiNose's Q1 2023 performance showed steady prescription demand and a strategic focus on profitability and growth.
While facing challenges like revenue decline and sales force impact, the company is poised for opportunities in market expansion and successful product launches.
Overall, OptiNose remains optimistic about meeting expectations and future approval, positioning itself for continued success in the pharmaceutical market.

OptiNose reports steady Q2 performance, eyes growth with new indications

OptiNose's Q2 2023 performance showed stable prescription demand and a strategic focus on the potential launch of a chronic sinusitis treatment in 2024.
While facing challenges like slightly lower net revenue and upcoming operating expenses, the company is well-positioned for growth opportunities.
With raised revenue guidance, a clear operating strategy, and ongoing FDA review, OptiNose is poised for potential revenue expansion and market growth.

OptiNose reports stable Q3 revenue, eyes growth through XHANCE launch

OptiNose's Q3 2023 performance showed stability in revenue and improved cost efficiency.
While facing challenges in prescription numbers, the company is strategically positioned for growth.
Opportunities lie in potential market expansion through new indications and partnerships.

OptiNose reports strategic growth in Q4 2023, eyes XHANCE approval

OptiNose's performance in Q4 2023 showcased progress in key areas, with a strategic focus on growth and efficiency. The company's financials reflected a reduction in expenses and a stable product demand, positioning it well for potential XHANCE approval and revenue expansion.

OptiNose reports strong Q1 performance and outlines growth strategies

OptiNose's Q1 2024 performance reflects growth in XHANCE net revenue and a strengthened financial position.
The company's strategic focus on chronic sinusitis launch and improved base business fundamentals bode well for future growth.
Opportunities lie in expanding sales efforts, international partnerships, and new product development for sustained value creation.

OptiNose reports Q3 revenue growth, adjusts full-year guidance

OptiNose's Q3 performance showed revenue growth and strategic adjustments.
While challenges like conservative guidance were raised, opportunities for growth exist.
Management's focus on execution and communication bodes well for future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

According to OptiNose's management, in 2021, the company's revenue will be at least $80 million, which is 62.9% more than in 2020. The company's gross margin is around 87%, well above the pharmaceutical industry average.

OptiNose: Undiscovered Gem

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2021 Results - Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates

Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 21.43% year over year to ($0.44), which missed the estimate of ($0.43).

OptiNose: Q2 Earnings Insights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Company Expects Top-Line Results in First Quarter 2022

Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

OptiNose's Xhance is already approved in one indication with another set to read out pivotal data from two trials in late 2021 and early 2022. Xhance had $48.4 million in sales in the sinusitis patients with nasal polyps in 2020 and looks to grow that to at least $80 million in 2021.

OptiNose: Growing Sales Make The Current Market Cap Look Very Low

Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System

Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry

YARDLEY, Pa., June 2, 2021 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists, today announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy & Rhinology, "Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps," recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatment of patients with nasal polyps.

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET.

Optinose to Present at the Jefferies Virtual Healthcare Conference

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2021 Results - Earnings Call Transcript

Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 22.22% year over year to ($0.49), which beat the estimate of ($0.53).

Recap: OptiNose Q1 Earnings

Company reports first quarter total revenue of $12.0 million

Optinose Reports First Quarter 2021 Financial Results and Operational Updates

OptiNose (NASDAQ:OPTN) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

OptiNose's Earnings: A Preview

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation

YARDLEY, Pa., April 27, 2021 /PRNewswire/ -- Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced results of a new nationwide survey on chronic nasal congestion, its impact on daily activities, and awareness of nasal polyps as a possible cause.

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day

OptiNose's (OPTN) CEO Peter Miller on Q4 2020 Results - Earnings Call Transcript

The stock price of OptiNose Inc (NASDAQ: OPTN) is trading at over 10% pre-market. This is why it happened.

OPTN Stock Price Increases Over 10% Pre-Market: Why It Happened

Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 20.69% over the past year to ($0.46), which were in line with the estimate of ($0.46).

Recap: OptiNose Q4 Earnings

OptiNose (NASDAQ:OPTN) unveils its next round of earnings this Wednesday, March 03. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Earnings Preview for OptiNose

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results

YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Tomas J. Heyman as a new director.

Optinose Announces Changes to Board of Directors

After COVID-19 slowed their commercial launch, OPTN is doing an exceptional job selling Xhance. Q3 2020 revenues grew ~50% from Q2 & consensus FY2021 revenue estimates forecast 100% growth. Professional analysts forecast $700MM in peak Xhance sales (some forecast peak sales in the billions/year). With a market cap of $220MM at $4.30/share, OPTN trades at .3X consensus peak sales.

News for OptiNose Stock (OPTN)